stents

drug elutin baloon_reestenosis_instrastent

Efficacy of Micromesh-Covered Stents in Carotid Artery Stenting

Most literature, old and recent, associates carotid artery stenting with a higher rate of stroke (although minor) when compared with carotid endarterectomy during the acute period. However, 30-day outcomes of angioplasty and surgery are comparable. Many technical advancements, including new stent designs and different cerebral protection mechanisms, have improved the outcomes of angioplasty in clinical<a href="https://solaci.org/en/2017/11/10/efficacy-of-micromesh-covered-stents-in-carotid-artery-stenting/" title="Read more" >...</a>

DEFINE FLAIR and IFR SWEDEHEART: Safety in Revascularization Based on FFR and iFR in Both Stable and ACS Patients

SYNTAX II: Better Stents, IVUS, FFR, or a Combination of All of Them to Catch Up with Surgery

In patients with 3-vessel disease, surgery obtained better outcomes than angioplasty, according to results from the SYNTAX and FREEDOM trials, which used first-generation drug-eluting stents. Even in the BEST trial, which used new-generation stents, surgery still offered far better outcomes. Nobody is surprised by the fact that, whenever angioplasty evolves due to a new device<a href="https://solaci.org/en/2017/09/13/syntax-ii-better-stents-ivus-ffr-or-a-combination-of-all-of-them-to-catch-up-with-surgery/" title="Read more" >...</a>

Los stent autoxpandibles son superiores a los de balón expandibles en el territorio ilíaco

Self-Expanding Stents Are Superior to Balloon-Expandable Stents in the Iliac Arteries

Courtesy of Dr. Carlos&nbsp;Fava. Severe atherosclerotic disease in&nbsp;iliac arteries is experienced by 15% of all men and 5% of all women. TAC&nbsp;II recommends&nbsp;angioplasty for type-A, -B, and -C lesions. As regards stent type, self-expanding stent (SE, more elasticity) vs. balloon-expandable stent (SB, more radial strength), Reekers indicates superior target lesion&nbsp;revascularization (TLR) with SE. However, there<a href="https://solaci.org/en/2017/09/05/self-expanding-stents-are-superior-to-balloon-expandable-stents-in-the-iliac-arteries/" title="Read more" >...</a>

¿Son los stents con polímero bioabsorbible más trombogénicos que los de segunda generación con polímero durable?

Are Bioresorbable-Polymer Stents More Thrombogenic than Durable-Polymer Second-Generation Stents?

Courtesy of Dr. Cristian Jesús Rodríguez. Most stents currently used in percutaneous coronary intervention (PCI) are durable-polymer second-generation drug-eluting stents (DP-DES, with everolimus or zotarolimus). However, it has been argued that the persistence of such a polymer after complete drug elution is one of the main factors for a dangerous complication: stent thrombosis (ST). After<a href="https://solaci.org/en/2017/08/23/are-bioresorbable-polymer-stents-more-thrombogenic-than-durable-polymer-second-generation-stents/" title="Read more" >...</a>

Los stents con polímeros biodegradables son tan seguros como los de polímeros permanentes en el seguimiento a 5 años

Biodegradable-polymer stents are as safe as permanent-polymer stents in a 5-year follow-up

Courtesy of Dr. Carlos&nbsp;Fava. One of the questions around drug-eluting stents (DES) is whether the development of biodegradable polymers would derive in better outcomes than the performance of durable polymers as regards the presence of events. In consequence, the COMPARE&nbsp;II trial was carried out with the aim of testing them in “real-world” patients. &nbsp; This<a href="https://solaci.org/en/2017/06/13/biodegradable-polymer-stents-are-as-safe-as-permanent-polymer-stents-in-a-5-year-follow-up/" title="Read more" >...</a>

BVS_everolimus

Promising Outcomes of Overlapping Stents in Patients Undergoing Bioresorbable Scaffold (BRS) Implantation

Courtesy of Dr. Guillermo Migliaro. In regular clinical practice, overlapping stents are reported in up to 30% of patients undergoing coronary angioplasty, especially due to very long lesions requiring implantation of multiple stents or dissection after the implantation of a first stent. &nbsp; In bare metal stent era, overlapping was associated with unfavorable clinical outcomes<a href="https://solaci.org/en/2017/05/08/promising-outcomes-of-overlapping-stents-in-patients-undergoing-bioresorbable-scaffold-brs-implantation/" title="Read more" >...</a>

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher<a href="https://solaci.org/en/2017/04/21/bioresorbable-scaffolds-with-drug-eluting-stents-do-they-entail-a-higher-thrombosis-risk/" title="Read more" >...</a>

Stents liberadores de biolimus y everolimus

Biolimus and Everolimus Eluting Stents in Coronary Artery Disease: Similar Safety?

Courtesy of Dr. Guillermo Migliaro. Events such as very late stent thrombosis and restenosis after first generation DES stenting were associated to the inflammatory response of site implantation. The presence of a durable or permanent polymer was thought to play a central role in said inflammatory process, which caused, among other things, delayed re-endothelialization and<a href="https://solaci.org/en/2017/04/01/biolimus-and-everolimus-eluting-stents-in-coronary-artery-disease-similar-safety/" title="Read more" >...</a>

trombosis plataformas bioabsorvibles

Very Late Thrombosis: Bioresorbable Scaffolds vs. Everolimus-Eluting Metallic Drug-Eluting Stents

This study sought to compare the 2-year outcomes between bioresorbable vascular scaffolds (BVS) and everolimus-eluting metallic drug-eluting stents (EES), since the occurrence of very late thrombosis (thrombosis beyond 1&nbsp;year after implantation) is an increasing concern in relation to new devices. &nbsp; This meta-analysis was conducted based on 24&nbsp;studies (BVS: n&nbsp;=&nbsp;2567 and EES: n&nbsp;=&nbsp;19,806) reporting the<a href="https://solaci.org/en/2017/01/24/very-late-thrombosis-bioresorbable-scaffolds-vs-everolimus-eluting-metallic-drug-eluting-stents/" title="Read more" >...</a>

Reestenosis de bordes con stents liberadores de everolimus

Edge Restenosis with Everolimus Eluting Stents: a few Predictors

Stent edge restenosis continues to be a weakness of drug eluting stents (DES). The aim of this study was to determine its predictors using optical coherence tomography (OCT). &nbsp; The study retrospectively analyzed 319 patients receiving OCT immediately after everolimus eluting stent implantation (EES) looking into the immediate outcome, and follow up angiography at 9<a href="https://solaci.org/en/2017/01/04/edge-restenosis-with-everolimus-eluting-stents-a-few-predictors/" title="Read more" >...</a>

Top